A 3-part, Phase 1, Single-center, Open-label Study to Assess the Relative Bioavailability of Oral Formulations for an Investigational Capsid Inhibitor in Healthy Adult Participants, and to Evaluate the Effect of Food on Bioavailability for an Investigational Capsid Inhibitor in Healthy Adult Participants
Latest Information Update: 06 Aug 2024
Price :
$35 *
At a glance
- Drugs VH 4004280 (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 02 Aug 2024 Status changed from recruiting to completed.
- 10 Jun 2024 Planned End Date changed from 18 Jun 2024 to 9 Sep 2024.
- 10 Jun 2024 Planned primary completion date changed from 18 Jun 2024 to 9 Sep 2024.